Latest News
Supernus Pharmaceuticals, Inc.
- Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervalued
- Supernus Pharmaceuticals, Inc. Estimates – NASDAQ:SUPN
- Form 8K Supernus Pharmaceuticals Inc For: 22 October By Investing.com
- FDA grants Supernus 7-year market exclusivity for Parkinson's drug
- FDA Grants Supernus Pharmaceuticals (SUPN) Seven Years of Orphan Drug Exclusivity for ONAPGO
- Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
- Supernus Pharmaceuticals Jumps 5.7% Amid Sector-Wide Rally
- Supernus Pharmaceuticals to Announce Third Quarter 2026
- Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
- Indivior Shareholders Approve Proposed Merger with Supernus
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD By Investing.com
- Form 4 Supernus Pharmaceuticals For: 6 October By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →